September 2008
Reactions Weekly;9/13/2008, Issue 1219, p8
Case Study
The article presents a case study of a 37-year-old man who developed human immunodeficiency virus (HIV)-associated lipodystrophy syndrome while receiving various antiretrovirals for HIV. The patient also developed anaemia during zidovudine therapy, peripheral neuropathy while receiving didanosine and stavudine, and a rash during treatment with efavirenz, then nevirapine. In February 2004, the patient started receiving a combination of tenofovir, lamivudine, lopinavir/ritonavir and fosamprenavir.


Related Articles

  • Rapidly growing lipoma as the syndrome of lipodystrophy in HIV-infected child. Mazur-Melewska, Katarzyna; Macedulski, Tomasz; Moryciński, Sebastian; Mania, Anna; Trejster, Ewa; Figlerowicz, Magdalena; Pohland, Justyna; Mańkowski, Przemysław; Służewski, Wojciech // Central European Journal of Medicine;Dec2012, Vol. 7 Issue 6, p753 

    Introduction: Lipomas are benign mesenchymal tumors composed of mature lipocytes grown in different parts of the body. The giant lipomas are very rare in children, however, highly active antiretroviral treatment (HAART) can increase their frequency. Case presentation: We present a case of a...

  • Antiretrovirals.  // Reactions Weekly;6/27/2009, Issue 1258, p6 

    The article describes the case of a 50-year-old HIV-positive man who experienced lipodystrophy with severe weight gain, dyslipidaemia and obstructive sleep apnoea. The patient received several treatments including cotrimoxazole, indinavir and lamivudine. He reported increased appetite and weight...

  • Lipodystrophy Syndrome by HAART in HIV-Infected Patients: Manifestation, Mechanisms and Management. Hirsch, H. H.; Battegay, M. // Infection;Oct2002, Vol. 30 Issue 5, p293 

    Progressive changes in the distributions of body fat and severe alterations of lipid, glucose and lactate levels challenge the mid and long-term success of highly active antiretroviral therapy of HIV-infection. Both clinical diagnosis of the lipodystrophy syndrome and scientific elucidation of...

  • Evaluation of Safety and Efficacy of Rosiglitazone in the Treatment of HIV-Associated Lipodystrophy Syndrome. Feldt, T.; Oette, M.; Kroidl, A.; Goebels, K.; Fritzen, R.; Kambergs, J.; Kappert, G.; Vogt, C.; Wettstein, M.; Häussinger, D. // Infection;Apr2006, Vol. 34 Issue 2, p55 

    Background: HIV-associated lipodystrophy syndrome (LDS) as a long-term side effect of HAART is becoming increasingly important and negatively affects adherence to medication. Currently, an effective therapy is not available. There is some evidence that the drug class of thiazolidindiones might...

  • Atazanavir interaction.  // Reactions Weekly;6/24/2006, Issue 1107, p7 

    The article discusses the case of a 66-year-old woman with HIV infection who developed lipodystrophy during antiretroviral treatment with atazanavir and concomitant ritonavir. It references a study by P. Dellamonica, published in the June 2006 issue of the "Journal of Infection." The medical...

  • Correction Options for Lipoatrophy in HIV-Infected Patients. Engelhard, Peter // AIDS Patient Care & STDs;Mar2006, Vol. 20 Issue 3, p151 

    Lipoatrophy (LA) is a form of lipodystrophy, characterized by volume depletion caused by fat loss in the limbs, buttocks, and face. Facial volume loss is the most obvious outward sign of LA because it alters the facial contours in the cheeks, temples, and orbits. Lipodystrophy and LA are most...

  • Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the Italian version of assessment of body change and distress questionnaire. Guaraldi, G.; Orlando, G.; Murri, R.; Vandelli, M.; de Paola, M.; Beghetto, B.; Nardini, G.; Ciaffi, S.; Vichi, F.; Wu, A. W.; Esposito // Quality of Life Research;Feb2006, Vol. 15 Issue 1, p173 

    Lipodystrophy (LD) includes morphologic changes that are distressing to patients with HIV. We tested the validity of an Italian version of the Assessment of Body Change and Distress (ABCD) questionnaire and analysed its relationship to physical and mental aspects of Health-Related Quality of...

  • Lipodystrophy Severity Does Not Contribute to HAART Nonadherence. Collins, Evan J.; Burgoyne, Robert W.; Wagner, Cheryl A.; Abbey, Susan E.; Halman, Mark H.; Nur, Margaret L.; Walmsley, Sharon L. // AIDS & Behavior;May2006, Vol. 10 Issue 3, p273 

    Lipodystrophy severity among 77 people living with HIV/AIDS (PHA) with body fat redistribution was not related to antiretroviral adherence including doses missed during the previous month, categorical rating of maximal adherence, and the PMAQ7 adherence behavior scale. Two thirds of the sample...

  • Rosigitazone Treatment for Fat Redistribution and Metabolic Abnormalities Caused by Anti-HIV Therapy.  // Annals of Internal Medicine;5/18/2004, Vol. 140 Issue 10, pI36 

    Presents questions and answers related to the article "Metabolic Effects of Rosiglitazone in HIV Lipodystrophy. A Randomized, Controlled Trial," from the same issue. Study of the possible use of the diabetes drug rosiglitazone to treat or prevent HIV lipodystrophy; Side effects of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics